Eli Lilly Reports Positive Early Results for Gene-Editing Cholesterol Therapy
Eli Lilly's Gene-Editing Therapy Lowers Cholesterol
Eli Lilly announced positive results from its phase 1b clinical trials for Verve-102, an experimental gene-editing treatment for high cholesterol. A single infusion reduced PCSK9 protein levels by up to 88% and lowered LDL cholesterol by as much as 62%.
Study Details
The phase 1b study involved adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. The treatment uses in vivo base editing to effectively turn off the PCSK9 gene in the liver, mimicking naturally occurring genetic variants that protect against heart disease.
Safety and Future Plans
Results were sustained for up to 18 months with no treatment-related serious adverse events. The FDA granted fast-track designation. Eli Lilly plans to start a phase 2 clinical study of Verve-102 by the end of the year.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…